Isoverticine

CAS No. 23496-43-7

Isoverticine( —— )

Catalog No. M29173 CAS No. 23496-43-7

Isoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 83 In Stock
5MG 126 In Stock
10MG 212 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Isoverticine
  • Note
    Research use only, not for human use.
  • Brief Description
    Isoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.
  • Description
    Isoverticine exhibits significant antitussive, expectorant and anti-inflammatory activities, it also displays significant cytotoxicity.(In Vitro):Isoverticine had significant cytotoxic activity, with IC50s of 49.56, 31.63, 61.91 and 108.8 μg/mL, respectively.
  • In Vitro
    Isoverticine displays cytotoxicity, with IC50s of 49.56, 31.63, 61.91 and 108.8 μg/mL, respectively.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    BCL
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    23496-43-7
  • Formula Weight
    431.661
  • Molecular Formula
    C27H45NO3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (231.67 mM)
  • SMILES
    [H][C@@]12CC[C@@]3([H])[C@@]([H])(CN4C[C@@H](C)CC[C@@]4([H])[C@@]3(C)O)[C@]1([H])C[C@@]1([H])[C@@]2([H])C[C@@H](O)[C@@]2([H])C[C@@H](O)CC[C@]12C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Lisaftoclax

    Bcl-2/Bcl-xl inhibitor 1 is a dual Bcl-2 and Bcl-xl inhibitor (IC50s: 2 nM and 5.9 nM for Bcl-2 and Bcl-xl) with anti-tumor activity. It is extracted from patent WO2018027097A1.

  • CID5721353

    BCL6 inhibitor 79-6 (Compound 79-6) is the first-generation, specific BCL6 BTB domain inhibitor with IC50 of 200 uM, Kd of 129 uM.

  • VU661013

    VU661013 (VU-661013) is a novel potent, selective MCL-1 inhibitor with Ki of 97 pM (human MCL-1) in TR-FRET assay.